Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5985499 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5986189 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5984173 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5985654 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5984500 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5984220 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5984468 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5984501 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5987306 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5986195 | 1.00 | FAAH (0.33) | FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023234426-A1 | ANTIBODY-MULTIDRUG CONJUGATE | ＵＢＥ株式会社 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023234427-A1 | ANTIBODY-MULTIDRUG CONJUGATE PRECURSOR AND SYNTHETIC INTERMEDIATE THEREOF | ＵＢＥ株式会社 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023163234-A1 | ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF | ＵＢＥ株式会社 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023163227-A1 | ANTIBODY-DRUG CONJUGATE | ＵＢＥ株式会社 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| US-8269038-B2 | Process for production of sulfonic acid ester | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20100041916-A1 | PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2067770-A1 | PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER | Wako Pure Chemical Industries, Ltd. (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-7018993-B2 | Antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041916-A1 | PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER | SULT1A1, SULT2A1, STS | FAAH 417/4885TRPV1 1855/4885 |
| US-20030158164-A1 | Novel antiandrogenic agent | NR5A1, CYP19A1, HSD17B11 | FAAH 1409/4885TRPV1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.